From Wikipedia, the free encyclopedia
|(what is this?)|
This drug was developed by Kyowa Hakko Kogyo Co., Ltd.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|